8-K: Butterfly Network Achieves Record Revenue in Q2 2024, Raises Adjusted EBITDA Guidance

Butterfly Network reported record quarterly revenue of $21.5 million in Q2 2024, a 16% year-over-year increase, and raised its full-year adjusted EBITDA guidance.

Summary

• Butterfly Network announced its second quarter 2024 financial results, achieving record revenue of $21.5 million, a 16% increase compared to the same period last year.
• The company's U.S. revenue grew by 3%, or 25% excluding the impact of large grant-based deployments in the prior year, while international revenue surged by 57%.
• Product revenue increased by 19% to $14.6 million, driven by higher selling prices of the iQ3 and a 4% increase in units fulfilled, or 37% excluding prior year medical school deployments.
• Software and other services revenue rose by 10% to $6.8 million, representing 32% of total revenue.
• Gross profit reached $12.6 million, with a gross margin of 58.6%, slightly down from 59.1% in the prior year due to product mix and higher amortization.
• Operating expenses decreased by 29% to $29.8 million, due to cost reductions and rationalization efforts.
• The net loss was reduced by 45% to $15.7 million, and the adjusted EBITDA loss improved to $8.1 million.
• The company's cash, cash equivalents, and restricted cash stood at $106.1 million as of June 30, 2024.
• Butterfly Network has affirmed its revenue guidance of $75 million to $80 million for fiscal year 2024, representing approximately 15-20% growth, and improved its adjusted EBITDA guidance to a loss of $50 million to $45 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to record revenue, reduced losses, and improved guidance. The company's strategic initiatives and technological advancements are also highlighted, contributing to a strong outlook.

Positives

• The company achieved record quarterly revenue, demonstrating strong sales performance.
• There was significant growth in international revenue, with a 57% increase year-over-year.
• The company has successfully reduced its net loss and operating expenses.
• The launch of the iQ3 and expansion into new markets are contributing to growth.
• The company has secured WHO endorsement for its iQ+ device, enhancing its global credibility.
• The company has extended its cash runway into 2027, providing financial stability.
• Butterfly has regained compliance with NYSE listing standards.

Negatives

• Gross margin decreased slightly to 58.6% due to product mix and higher amortization.
• U.S. revenue growth was impacted by the absence of large grant-based deployments from the prior year.
• The company is still operating at a net loss, although it has been significantly reduced.

Risks

• The company's ability to sustain its growth trajectory and achieve profitability remains a risk.
• The company's reliance on new product launches and market expansion could be impacted by unforeseen challenges.
• The company's ability to maintain compliance with NYSE listing standards is an ongoing concern.
• The company's forward-looking statements are subject to various risks and uncertainties, including market acceptance of its products and regulatory approvals.

Future Outlook

Butterfly Network has affirmed its revenue guidance of $75 million to $80 million for fiscal year 2024, representing approximately 15-20% growth, and improved its adjusted EBITDA guidance to a loss of $50 million to $45 million.

Management Comments

• Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman, stated that Butterfly continues to achieve remarkable milestones driven by the launch of Butterfly iQ3.
• DeVivo also noted that the company exceeded expectations despite facing its toughest comparison quarter of the year.
• DeVivo expressed confidence in the company's ability to sustain momentum and deliver continued value to shareholders.

Industry Context

This announcement highlights Butterfly Network's continued growth in the digital health and medical imaging space, particularly with its innovative handheld ultrasound technology. The company's expansion into new markets and partnerships aligns with the broader trend of increasing adoption of portable and AI-powered medical devices.

Comparison to Industry Standards

• Butterfly Network's 16% year-over-year revenue growth in Q2 2024 is a strong performance compared to some established medical device companies, such as Philips and GE Healthcare, which have seen more modest growth in recent quarters.
• The company's focus on portable ultrasound technology and AI integration positions it well against competitors like Clarius Mobile Health and SonoSite, which also offer handheld ultrasound devices.
• The reduction in net loss and operating expenses demonstrates improved financial discipline, which is crucial for long-term sustainability and is a positive sign compared to other high-growth companies in the medical technology sector that are still struggling with profitability.
• The WHO endorsement of Butterfly iQ+ is a significant achievement, setting it apart from many competitors and opening up opportunities in low-resource settings, a market that is often overlooked by larger medical device companies.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and positive outlook.
• Employees will be impacted by the company's cost reduction initiatives and strategic investments.
• Customers will benefit from the company's innovative products and services.
• The company's expansion into new markets will impact suppliers and partners.

Next Steps

• The company will continue to focus on expanding its market reach and enhancing its technological capabilities.
• Butterfly will continue to develop AI advancements and new development partnerships.
• The company will continue to engage foreign governments and funders for global health initiatives.
• Butterfly will continue to monitor and comply with NYSE listing standards.

Key Dates

Keywords

Ultrasound, Medical Imaging, Digital Health, Butterfly Network, Financial Results, Revenue Growth, EBITDA, iQ3, NYSE, Healthcare Technology